NCT02431845 Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder
| NCT ID | NCT02431845 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Severance Hospital |
| Condition | Obsessive-Compulsive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2013-01-01 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2013-01-01 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine whether pharmaco(epi)genetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.
Eligibility Criteria
Inclusion Criteria: 1. age 19\~ 70 2. OCD by Diagnostic and Statistical Manual for Mental disorders, 4th edition (DSM-IV) 3. drug naive or drug free for more than 3 months Exclusion Criteria: 1. any neurological disorder 2. comorbid psychotic disorders 3. alcohol or other substance dependence within past 6 months 4. any evidences for brain diseases
Contact & Investigator
Se Joo Kim, M.D.
PRINCIPAL INVESTIGATOR
Professor, Department of Psychiactry, Yonsei Univ. College of Medicine
Frequently Asked Questions
Who can join the NCT02431845 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 70 Years, studying Obsessive-Compulsive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02431845 currently recruiting?
Yes, NCT02431845 is actively recruiting participants. Contact the research team at kimsejoo@yuhs.ac for enrollment information.
Where is the NCT02431845 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT02431845 clinical trial?
NCT02431845 is sponsored by Severance Hospital. The principal investigator is Se Joo Kim, M.D. at Professor, Department of Psychiactry, Yonsei Univ. College of Medicine. The trial plans to enroll 200 participants.